TP-3654 is primarily investigated for its potential in cancer therapy, particularly targeting PIM kinases, which play a role in cell survival and proliferation. Its application focuses on inhibiting these kinases to suppress tumor growth, making it a candidate for treating various cancers, including hematologic malignancies and solid tumors. Research is ongoing to evaluate its efficacy and safety in preclinical and clinical settings.